Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer

Overview of attention for article published in Cell, October 2017

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (98th percentile)

Mentioned by

news: 58 news outlets
blogs: 6 blogs
policy: 1 policy source
twitter: 167 X users

patent: 23 patents
facebook: 1 Facebook page
f1000: 1 research highlight platform
guideline: 5 clinical guideline sources

Readers on

mendeley: 1183 Mendeley
citeulike: 1 CiteULike

So far, Altmetric has seen 76 news stories from 58 outlets.

Bladder cancer: still waiting for the right wave?

Thelimbic, 24 Jul 2024

Precision oncology has much to offer in the management of bladder cancer which has seen little improvement in survival over the…

New Tool IDs Immunotherapy-Responsive Bladder Cancer

MedPage Today, 28 Sep 2023

This Reading Room is a collaboration between MedPage Today® and: A new risk assessment tool was able to reliably identify…

Bladder cancer: management

Pharmaceutical Journal, 10 May 2022

After reading this article, you should be able to: Differentiate the types of bladder cancer; Understand the treatment options…

Astellas and Seagen Announce CHMP Confirms Positive Opinion for PADCEV(TM) (enfortumab vedotin) in Locally Advanced or Metastatic Urothelial Cancer

Futures TradingCharts.com, 28 Feb 2022

Astellas Pharma Inc. (TSE:4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seagen Inc.

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 72 additional news stories.